March 1-3, 2021

Please note that due to COVID-19, AGBT 21 WILL NOW BE VIRTUAL.
The safety of all our participants is of utmost importance. We look forward to sharing your scientific advances with people from across the globe. Be safe, stay well, and we will look forward to showcasing your science in March.



Advances in Genome Biology and Technology (AGBT) is considered the preeminent genome science and technology conference where top global researchers, leaders and innovators meet to announce new discoveries, cutting edge breakthroughs and to collaborate. As a recognized cornerstone for the genomics research community, AGBT provides an outstanding forum for exchanging information about the latest advances in DNA sequencing technologies, experimental and analytical approaches for genomic studies, and their myriad of applications. The meeting format includes daytime plenary sessions that feature invited speakers and abstract-selected talks that highlight cutting-edge research across the broad landscape of genomics. The evening concurrent session includes experimental and computational approaches for effectively utilizing the latest DNA sequencing technologies.

Registration Type

Early Registration* (by 12/16/20)

Regular Registration (after 12/16/20)










*Early bird attendees will receive our AGBT swag box.

Submitting an Abstract?

Abstracts may be submitted online between September 10, 2020 and September 30, 2020 at 3:00pm CDT.

Abstracts submitted after September 30, 2020 will be considered as late-breaking abstracts.

Once your abstract has been submitted, you will receive a confirmation email.  If you do not receive an email confirmation within 12 hours of submitting an abstract, please email

The total length of the abstract should not exceed 400 words.

Only one presenting author may be specified per abstract.

With appropriate approval, abstracts discussing late-breaking scientific discoveries will be accepted as late as December 14, 2020 at 3:00pm CST.
Link below will open in a new window to submit an abstract.